- Home
- APLS vs OGN Comparison
APLS vs OGN Comparison
Compare APLS & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- OGN
- Stock Information
- Founded
- APLS 2009
- OGN 1923
- Country
- APLS United States
- OGN United States
- Employees
- APLS N/A
- OGN N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- APLS Health Care
- OGN Health Care
- Exchange
- APLS Nasdaq
- OGN Nasdaq
- Market Cap
- APLS 2.2B
- OGN 2.5B
- IPO Year
- APLS 2017
- OGN N/A
- Fundamental
- Price
- APLS $18.90
- OGN $9.96
- Analyst Decision
- APLS Buy
- OGN Hold
- Analyst Count
- APLS 19
- OGN 4
- Target Price
- APLS $37.61
- OGN $18.00
- AVG Volume (30 Days)
- APLS 2.1M
- OGN 3.5M
- Earning Date
- APLS 07-31-2025
- OGN 08-05-2025
- Dividend Yield
- APLS N/A
- OGN 0.80%
- EPS Growth
- APLS N/A
- OGN N/A
- EPS
- APLS N/A
- OGN 2.88
- Revenue
- APLS $775,839,000.00
- OGN $6,294,000,000.00
- Revenue This Year
- APLS $8.00
- OGN N/A
- Revenue Next Year
- APLS $13.82
- OGN $1.11
- P/E Ratio
- APLS N/A
- OGN $3.46
- Revenue Growth
- APLS 48.04
- OGN N/A
- 52 Week Low
- APLS $16.10
- OGN $8.01
- 52 Week High
- APLS $41.94
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- APLS 51.99
- OGN 49.67
- Support Level
- APLS $19.16
- OGN $9.55
- Resistance Level
- APLS $20.40
- OGN $10.22
- Average True Range (ATR)
- APLS 0.93
- OGN 0.26
- MACD
- APLS -0.04
- OGN 0.02
- Stochastic Oscillator
- APLS 32.64
- OGN 53.66
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.